Moteur de recherche d’entreprises européennes
Financement de l’UE (6 840 000 €) : Développer de nouveaux actifs (une entité moléculaire pré-nouvelle et un premier démarrage chez l’homme) pour la tuberculose qui agissent en synergie avec les … Hor01/05/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Développer de nouveaux actifs (une entité moléculaire pré-nouvelle et un premier démarrage chez l’homme) pour la tuberculose qui agissent en synergie avec les inhibiteurs de la bédaquiline, du cytochrome bc ou du cytochrome bd
Despite recent progress in biomedical research, Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is still the world’s leading infectious disease killer worldwide. In addition, multi-drug TB is the largest single contributor to anti-microbial resistance and poses a serious threat to global health. Treatment options are limited, and expensive, recommended medicines are not always available in many countries, and patients experience many adverse effects from the drugs. Moreover, due to the long treatment duration, compliance is low leading to more AMR in TB. Thus, there is an acute need for the development of a novel combination regimen with an indication for effective, shorter, and safer treatment of all forms of TB. The overall objective of RESPIRI-TB is to find new drug candidates as potential components of a new, more efficient combination drug regimen against TB that is less prone to resistance and allows shortening of treatment duration for TB, and multidrug-resistant TB. Such a drug combination will synergistically target the energy metabolism of Mtb or complementary targets. To achieve this, we will advance recently discovered inhibitors of the Mtb respiratory pathway. In addition, we will target the Mtb specific molecular mechanism that reduces reactive oxygen species in the cell. Finally, we will also target host-factors that are essential for the intracellular survival of Mtb. Together, we present a comprehensive plan to find novel strategies to combat TB, shorten treatment time and reduce chances of drug resistance.
| Academisch Ziekenhuis Leiden | 1 074 533 € |
| Ffund B.V. | 211 036 € |
| Janssen Pharmaceutica N.V. | 0,00 € |
| Kobenhavns Universitet | 99 639 € |
| Medizinische Universitaet Wien | 840 189 € |
| Mitologics | 146 631 € |
| Sorbonne Universite | 343 875 € |
| Universiteit Antwerpen | 3 999 723 € |
| Universiteit Leiden | 124 375 € |
https://cordis.europa.eu/project/id/853903
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
